LFG
RXRX icon

Larson Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Larson Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-501
Closed -$1.54K – 3899
2026
Q1 		$1.54K Hold
501
– – ﹤0.01% 3034
2025
Q4 		$2.05K Buy
501
+496
+9,920% +$2.46K ﹤0.01% 2779
2025
Q3 		$24 Buy
+5
New +$26 ﹤0.01% 3388
2024
Q4 		– Sell
-207
Closed -$1.36K – 2885
2024
Q3 		$1.36K Sell
207
-101
-33% -$724 ﹤0.01% 1922
2024
Q2 		$2.31K Buy
308
+199
+183% +$1.74K ﹤0.01% 1575
2024
Q1 		$1.09K Buy
+109
New +$1.21K ﹤0.01% 1438

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Larson Financial Group's RXRX Position: Q2 2026 in Review

Larson Financial Group sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 501 shares — an estimated $1.54K sold.

Larson Financial Group first reported a position in RXRX in Q1 2024 and held it in 6 quarters. The position peaked at $2.31K in Q2 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Larson Financial Group reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Larson Financial Group sold 501 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.54K.
  • Larson Financial Group first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Larson Financial Group's Recursion Pharmaceuticals position peaked at $2.31K in Q2 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.